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OPEN
ORIGINAL ARTICLE
Methylomic analysis of monozygotic twins discordant for autism
spectrum disorder and related behavioural traits
CCY Wong1, EL Meaburn1,2, A Ronald1,2, TS Price1,3, AR Jeffries1, LC Schalkwyk1, R Plomin1 and J Mill1,4
Autism spectrum disorder (ASD) deﬁnes a group of common, complex neurodevelopmental disorders. Although the aetiology of
ASD has a strong genetic component, there is considerable monozygotic (MZ) twin discordance indicating a role for non-genetic
factors. Because MZ twins share an identical DNA sequence, disease-discordant MZ twin pairs provide an ideal model for examining
the contribution of environmentally driven epigenetic factors in disease. We performed a genome-wide analysis of DNA
methylation in a sample of 50 MZ twin pairs (100 individuals) sampled from a representative population cohort that included twins
discordant and concordant for ASD, ASD-associated traits and no autistic phenotype. Within-twin and between-group analyses
identiﬁed numerous differentially methylated regions associated with ASD. In addition, we report signiﬁcant correlations between
DNA methylation and quantitatively measured autistic trait scores across our sample cohort. This study represents the ﬁrst
systematic epigenomic analyses of MZ twins discordant for ASD and implicates a role for altered DNA methylation in autism.
Molecular Psychiatry (2014) 19, 495–503; doi:10.1038/mp.2013.41; published online 23 April 2013
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INTRODUCTION
Autism spectrum disorder (ASD) deﬁnes a collection of complex
childhood neurodevelopmental disorders affecting B1% of the
population and conferring severe lifelong disability.1 ASD is
characterized by a triad of impairments: (1) deﬁcits in social
interactions and understanding, (2) non-social impairments, such
as repetitive behaviour and interests, and (3) impairments in
language and communication development. Quantitative genetic
studies indicate that ASD has a strong heritable component,2
which is supported by the recent identiﬁcation of several
susceptibility loci and an emerging literature implicating the
relevance of de novo and inherited copy number variants (CNVs) in
the disorder.3 Despite intense research effort during the past
decade, however, no deﬁnitive biological or clinical markers for
ASD have been identiﬁed. This can be partly explained by the
highly heterogeneous nature of ASD, both clinically and
aetiologically. The clinical manifestation of ASD displays
considerable individual variability in the severity of impairments
and quantitative genetic studies also report genetic heterogeneity
between the three trait domains of ASD.4–6
Despite the high heritability estimates for ASD, there is notable
discordance within monozygotic (MZ) twin pairs for diagnosed
ASD, and often considerable symptom severity differences within
ASD-concordant MZ twins,2 strongly implicating a role for non-
genetic epigenetic factors in aetiology. Epigenetic mechanisms
mediate reversible changes in gene expression independent of
DNA sequence variation, principally through alterations in DNA
methylation and chromatin structure.7 Epigenetic changes in the
brain have been associated with a range of neurological and
cognitive processes, including neurogenesis,8 brain development9
and drug addiction.10 Emerging evidence implicates epigenetic
modiﬁcations in several neuropsychiatric disorders, including
ASD.11,12 In particular, epigenetic dysregulation underlies the sym-
ptoms of Rett syndrome and Fragile X syndrome, two disorders
with considerable phenotypic overlap with ASD.11 Although few
empirical studies have systematically examined the role of altered
epigenetic processes in ASD, recent analyses provide evidence for
altered DNA methylation and histone modiﬁcations in disease
pathology.13–15
The use of disease-discordant MZ twins represents a powerful
strategy in epigenetic epidemiology because identical twins
are matched for genotype, age, sex, maternal environment,
population cohort effects and exposure to many shared environ-
mental factors.16,17 Recent studies have uncovered considerable
epigenetic variation between MZ twins,18–20 and DNA methylation
differences have been associated with MZ twin discordance for
several complex phenotypic traits, including psychosis21 and Type
1 diabetes.22 In ASD, Nguyen and co-workers23 recently examined
lymphoblastoid cell lines derived from peripheral blood lympho-
cytes collected from three ASD-discordant MZ twin pairs, reporting
several ASD-associated differentially methylated loci.23 Two loci
(RORA and BCL2) reported as hypermethylated in ASD were found
to be downregulated in RNA from post-mortem autism brains.
These ﬁndings support a role for DNA methylation in ASD and
highlight the successful use of peripherally derived DNA from
discordant MZ twins to identify disease-associated epigenetic
changes. Given the highly heterogeneous nature of ASD, however,
more comprehensive genome-wide analyses across larger numbers
of samples are warranted to investigate the extent to which ASD-
associated epigenetic variation is individual- and symptom-speciﬁc.
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MATERIALS AND METHODS
Samples for methylomic analysis
Participants were recruited from the Twins’ Early Development Study
(TEDS), a United Kingdom-based study of twins contacted from birth
records.24 For this study, a total of 50 MZ twin pairs were identiﬁed within
TEDS using the Childhood Autism Symptom Test (CAST), which assesses
dimensional ASD traits, at age 8 years. The CAST25 is a 31-item screening
measurement for ASD, designed for parents and teachers to complete in
non-clinical settings to assess behaviours characteristic of the autistic
spectrum. Items within the CAST are scored additively and a score ofX15
(that is, answering ‘yes’ onX15 items) is the cutoff for identifying children
‘at risk’ for ASD. On the basis of the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition criteria for autism, CAST items can be
divided into three subscales: impairments in social symptoms (12 items);
impairments in non-social symptoms (that is, restricted repetitive
behaviours and interests (RRBIs); 7 items); and communication
impairments (12 items).6 The CAST has been widely used in population-
based studies of singletons25 as well as in twin studies.26 Within TEDS, the
CAST has been shown to have good reliability and validity.27
Supplementary Figure 1 shows the distribution of total CAST and its three
subscale scores within samples selected using parent ratings.
Supplementary Table 1 provides a summary of the samples included in
the analyses. Whole-blood samples were collected from subjects at age 15
years by a trained phlebotomist for DNA extraction and blood cell-count
analysis. Blood cell counts were assessed for all collected samples and
found to be within the normal range.
Genome-wide analysis of DNA methylation
For each individual, genomic DNA (500 ng) extracted from whole blood
was treated with sodium bisulphite using the EZ 96-DNA methylation kit
(Zymo Research, Irvine, CA, USA) following the manufacturer’s standard
protocol. The bisulphite conversion reaction was performed in duplicate
for each sample to minimize potential bias caused by variable conversion
efﬁciency, and pooled bisulphite-treated DNA was used for subsequent
array analysis. Genome-wide DNA methylation was assessed using the
Illumina Inﬁnium HumanMethylation27 BeadChip (Illumina, San Diego, CA,
USA), which interrogates the DNA methylation proﬁle of 27 578 CpG
sites located in 14 495 protein-coding gene promoters and 110 microRNA
gene promoters, at single-nucleotide resolution.28 Illumina GenomeStudio
software (Illumina, San Diego, CA, USA) was used to extract signal
intensities for each probe and perform initial quality control checks,
with all data sets (except two individuals) being considered to be of
high quality and included in subsequent analyses. To ensure stringent
data quality, probes with a detection P-value 40.05 in any of the
samples were removed across all individuals (N¼ 1161 probes) in
addition to a set of probes (N¼ 2923) that were reported as nonspeciﬁc
and potentially unreliable in a recent survey of all probes on the
microarray.29
Methylation microarray data processing
All computations and statistical analyses were performed within the R
statistical analysis environment (http://www.r-project.org), and all analysis
scripts are available on request from the authors. A customized pipeline
was used for the analysis of Illumina 27K methylation data as described in
a previous study of psychosis-discordant MZ twins.21 Brieﬂy, signal
intensities for each probe were normalized using quantile normalization
to reduce unwanted interarray variation. The relative methylation level of
each interrogated CpG site was calculated as the ratio of the normalized
signal from the methylated probe to the sum of the normalized signals of
the methylated and unmethylated probes. This gave an average DNA
methylation value, described as average ‘b-value’ for each CpG site,
ranging from 0 (unmethylated) to 1 (fully methylated). A density plot of
b-values for every sample revealed that, as expected given the known
distribution of probes on the array, the data followed a bimodal
distribution (Supplementary Figure 2). An empirical variance stabilizing
transformation was used to adjust for the bimodal distribution of the
data.21 Raw microarray data are available for download from http://
epigenetics.iop.kcl.ac.uk/ASDTwins/.
Identiﬁcation of ASD-associated DMRs
Two major analysis strategies were used to identify DMRs associated with
ASD and related traits. First, DNA methylation differences within pairs of
MZ twins were examined in MZ twin pairs discordant for ASD and ASD-
related traits. Second, case–control comparisons of DNA methylation were
performed between groups of individuals scoring high and low for ASD
traits. With the aim of identifying real, biologically relevant within-twin and
between-group DNA methylation differences, we used an analytic
approach that incorporates both the signiﬁcance (that is, t-test statistic)
and magnitude (that is, absolute delta-b (Db)) of any observed differences
to produce a ranked list of DMRs.21 A summary of the analysis strategy is
presented in Supplementary Figure 3. This combined approach, where
data are interpreted based on the combination of fold change and
statistical signiﬁcance, is routinely used in genome-wide gene expression
studies and has been shown to produce gene lists of higher reproducibility
and biological relevance.30 We recently used a similar approach
successfully to identify disease-associated epigenetic changes in a
psychosis-discordant MZ twin study.21 Given the known phenotypic and
aetiologic heterogeneity, we also screened for large Db-values within each
discordant MZ twin pair to examine the possibility that disease-associated
epigenetic changes are potentially private and not consistent across all
families. Finally, we examined whether quantitative CAST scores are
correlated with DNA methylation at speciﬁc loci. The association between
each of the quantitatively rated CAST subscale variables and DNA
methylation at each CpG site was assessed using Pearson’s product–
moment correlation.
Global DNA methylation analysis
Global levels of DNA methylation were quantiﬁed using the LUminometric
Methylation Assay (LUMA).31 This method relies on DNA cleavage by
methylation-sensitive and -insensitive restriction enzymes, followed by
the quantiﬁcation of the resulting restriction fragments using
pyrosequencing.31 Positive controls, including both artiﬁcially methylated
and artiﬁcially unmethylated samples, were included in all experimental
steps to ensure unambiguous restriction enzyme digestions and to
calibrate the experimental data, with each sample being processed in
duplicate.
Fine mapping of DNA methylation using bisulphite
pyrosequencing
Although the Illumina 27K array has been well validated for detecting
differences in DNA methylation, we further tested speciﬁc regions
nominated from the genome-wide microarray analysis using bisulphite
pyrosequencing. Independent veriﬁcation analyses were performed on
two CpG sites (cg16474696, MGC3207; cg20507276, OR2L13) that demon-
strated a large signiﬁcant ASD-associated difference from the case versus
control analysis. In each case, the assay spanned multiple CpG sites,
including the speciﬁc CpG interrogated on the Illumina 27K array. Brieﬂy,
500 ng DNA from each individual was independently treated with sodium
bisulphite in duplicate using the EZ 96-DNA methylation kit as described
above. Bisulphite-polymerase chain reaction ampliﬁcation was performed
in duplicate. Quantitative DNA methylation analysis was conducted using
the PyroMark Q24 pyrosequencer (Qiagen, Valencia, CA, USA). The
correlation between DNA methylation estimates obtained from Illumina
27K array and bisulphite pyrosequencing was assessed using Pearson’s
moment–correlation coefﬁcient. In addition, Sanger sequencing using
BigDye v.3.1 terminator mix (Applied Biosystems, Foster City, CA, USA)
was performed on the regions targeted by the MGC3207 pyrosequencing
assay to ensure that the Illumina probe sequences and the primer binding
sites for the pyrosequencing assay were free of any DNA sequence
variation. The primers and assay conditions are given in Supplementary
Table 2.
CNV analysis using genotyping arrays
Genomic DNA (200 ng) extracted from whole blood was genotyped using
the Illumina HumanOmniExpress BeadChip (Illumina) targeting 4730 000
single-nucleotide polymorphisms and Illumina GenomeStudio software
was used to call genotypes based on predeﬁned genotype cluster
boundaries to denote cluster positions (HumanOmniExpress-12v1_C.egt).
CNVs were identiﬁed from the genotyping data using two independent
algorithms, PennCNV32 and QuantiSNP,33 with default parameters, and GC
content signal preprocessing was applied. Stringent quality control steps
were used to ensure that only high-conﬁdence CNVs, that is, those 41 kb
in size, covered by 45 probes and detected by both programs, were
included for further analysis.
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RESULTS
ASD is not associated with systemic differences in global DNA
methylation
As expected, within-twin patterns of DNA methylation were highly
correlated across all MZ twin pairs (average within-twin r across all
probes¼ 0.99), indicating that ASD and related traits are not
associated with systemic changes in epigenetic programming.
Supplementary Figure 4a shows the correlation between genome-
wide DNA methylation across all probes on the array and
one example ASD-discordant MZ twin pair; data for the other
ASD-discordant MZ pairs are available for download from http://
epigenetics.iop.kcl.ac.uk/ASDTwins/. These data were corroborated
by global DNA methylation analysis using LUMA, which identiﬁed
no signiﬁcant difference between affected ASD twins and their
co-twins (affected ASD twins mean¼ 65.1%, unaffected co-twins
mean¼ 65.9%; P¼ 0.817) (Supplementary Figure 4b).
Site-speciﬁc DNA differences are widespread in MZ-discordant
ASD twins
In contrast to global levels of DNA methylation, DNA methylation
at individual CpG sites demonstrated considerable variability
within ASD-discordant MZ twin pairs. Figure 1a shows the
distribution of average absolute differences in DNA methylation
(Db) within all MZ twins discordant for ASD and ‘control’ MZ twin
pairs concordant for low autistic trait score (unaffected). The
overall distribution of average within-pair DNA methylation
differences showed a highly signiﬁcant skew to the right in
ASD-discordant twins (Po2.2e 16, Kolmogorov–Smirnov test),
with a higher number of CpG sites demonstrating a larger average
difference in DNA methylation. Using an analysis method
designed to identify the largest and most signiﬁcant differences
in DNA methylation at individual CpG sites, we identiﬁed multiple
CpG sites across the genome exhibiting signiﬁcant ASD-associated
differential DNA methylation (Table 1). Of note, variability at these
sites appears to be speciﬁc to ASD-discordant twin pairs; for the 50
top-ranked ASD-associated DMRs, we observe signiﬁcantly higher
average within-pair differences for MZ twin pairs discordant for
ASD (Po0.01; see Figure 1b). The top differentially methylated site
(cg13735974) across all ASD-discordant MZ twin pairs located in
the NFYC promoter was consistently hypermethylated in affected
individuals compared with their unaffected co-twins (mean
Db¼ 0.08, range¼ 0.04–0.10, Po0.0004). For the top 10 DMRs,
Figure 2 indicates highly consistent differences across all six ASD-
discordant twin pairs.
Large DNA methylation differences are observed at speciﬁc loci
within individual ASD-discordant MZ twin pairs
Because ASD is a highly heterogeneous disorder,3 it is probable
that many disease-associated DMRs are family-speciﬁc. We there-
fore screened for the largest family-speciﬁc DNA methylation
differences within each discordant ASD twin pair, identifying
numerous loci (average¼ 37.4 per twin pair) showing large DNA
methylation differences (DbX0.15) within each discordant twin
pair (Supplementary Figure 5 and Supplementary Table 3).
Although the majority of DMRs of large magnitude are family-
speciﬁc, several are common across two or more discordant twin
Figure 1. (a) A significantly (Po2.2E 16) higher number of CpG sites with a large average within-twin b differences was observed in autism
spectrum disorder (ASD)-discordant monozygotic (MZ) twin pairs compared with unaffected twin pairs (that is, concordant for low Childhood
Autism Symptom Test (CAST) score). (b) Absolute mean Db of the top 50 differentially methylated CpG sites in ASD-discordant MZ twin pairs
and in unaffected MZ twin pairs.
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pairs in the same direction: cg12164282, located in PXDN
promoter, showed ASD hypomethylation in twin pair 2 (Db¼
 0.19) and twin pair 4 (Db¼  0.28); cg04545708, located in
exon 1 of C11orf1, showed ASD hypermethylation in both twin
pair 3 (Db¼ 0.23) and twin pair 6 (Db¼ 0.35); cg20426860, located
in exon 1 of TMEM161A, showed ASD hypermethylation in twin
pair 4 (Db¼ 0.21) and twin pair 6 (Db¼ 0.27); and cg27009703,
located in HOXA9 promoter, showed ASD hypermethylation in
twin pair 1 (Db¼ 0.19) and twin pair 4 (Db¼ 0.21).
DNA methylation differences are observed in MZ twins discordant
for ASD-related traits
We detected signiﬁcant DNA methylation differences between MZ
twin pairs discordant for the three ASD-associated traits: that is,
social autistic traits (N¼ 9 MZ pairs), autistic RRBIs (N¼ 9 MZ pairs)
and communication autistic traits (N¼ 8 MZ pairs). The top-ranked
DMRs for each trait are shown in Supplementary Figure 6 and
Supplementary Table 4. Interestingly, these included several genes
previously implicated in the aetiology of ASD, including GABRB3,
AFF2, NLGN2, JMJD1C, SNRPN, SNURF, UBE3A and KCNJ10.
As ASD is composed of a triad of all three impairments, we also
examined if any CpG sites are differentially methylated across all
discordant twin pairs (N¼ 32 pairs, 64 individuals), regardless of
their focal impairment. The top DMRs across all discordant twin
pairs are shown in Supplementary Figure 7 and Supplementary
Table 5. The top-ranked DMR located in the promoter region of
PIK3C3 (cg19837131) was signiﬁcantly hypomethylated in affected
individuals compared with their unaffected co-twins (mean Db¼
Table 1. The top 50 differentially methylated CpG sites identified in ASD-discordant MZ twin pairs, ranked by statistical significance and mean Db
(calculated as DNA methylation level of ASD twin minus well twin)
Rank ProbeID Gene Chr. Position Mean Db P-value
1 cg13735974 NFYC 1 4092 9567 0.08 3.63E 04
2 cg27321538 DNPEP 2 2 1996 0475 0.05 1.33E 03
3 cg01447498 TSNAX 1 22 9731 294 0.05 9.68E 04
4 cg08142684 TCP1 6 160 129 858  0.06 4.29E 03
5 cg11241627 FERD3L 7 19 151 690  0.07 4.74E 03
6 cg20372689 RCN2 15 75 010 774 0.05 2.08E 03
7 cg21195120 MBTPS2 X 21 768 225  0.05 3.47E 03
8 cg04689061 PKIA 8 79 590 548 0.08 6.55E 03
9 cg21614638 DAPP1 4 100 956 844 0.05 3.48E 03
10 cg02639007 CCDC41 12 93 377 476 0.05 4.90E 03
11 cg15700739 HOXC5 12 52 713 967 0.04 8.79E 04
12 cg12148581 RPL14 3 40 473 347 0.05 6.67E 03
13 cg25118574 PSMB7 9 126 217 467 0.05 5.09E 03
14 cg06284322 TAF7 5 140 680 846  0.05 7.30E 03
15 cg23397015 INHBB 2 120 818 902  0.05 8.95E 03
16 cg12241297 HNRPA0 5 137 118 306 0.05 9.57E 03
17 cg13588354 MC3R 20 54 256 710 0.04 4.27E 03
18 cg10528989 BDKRB1 14 95 792 059 0.04 5.48E 03
19 cg15836394 FDFT1 8 11 697 241 0.04 1.61E 03
20 cg21935083 RAD50 5 131 920 213 0.05 1.16E 02
21 cg03660451 RECQL5 17 71 176 201  0.04 2.80E 03
22 cg16166399 ZNF499 19 63 722 565 0.06 1.30E 02
23 cg23627134 ARHGAP15 2 143 602 845 0.05 1.16E 02
24 cg05751148 PTPRCAP 11 66 961 375 0.04 3.48E 03
25 cg18284523 TINF2 14 23 781 402 0.04 8.23E 03
26 cg20346096 C18orf22 18 75 895 818  0.04 1.96E 04
27 cg07200280 RAFTLIN 3 16 529 623  0.04 3.34E 03
28 cg12624641 C14orf143 14 89 490 322 0.04 8.96E 03
29 cg01253545 RNF185 22 29 886 314  0.06 1.48E 02
30 cg17367215 SUPT5H 19 44 628 460  0.04 3.15E 03
31 cg01894895 ANXA1 9 74 956 114  0.05 1.32E 02
32 cg24687764 C16orf46 16 79 668 575  0.04 1.12E 02
33 cg20917484 GAPDH 12 6 514 327  0.04 1.74E 03
34 cg18776056 FKBP4 12 2 775 173  0.04 1.40E 03
35 cg19674669 LOC112937 11 133 652 120 0.04 2.91E 03
36 cg03875195 SLC30A3 2 27 339 867  0.04 1.09E 02
37 cg05520656 ZNF681 19 23 733 431 0.04 8.51E 03
38 cg18515587 SELENBP1 1 149 611 430 0.04 6.46E 03
39 cg07239938 ELA2 19 803 813 0.04 9.48E 03
40 cg01148741 DUSP2 2 96 175 180  0.05 1.40E 02
41 cg17002259 CDC42SE1 1 149 298 884 0.04 8.37E 03
42 cg02154186 PNMA2 8 26 427 270  0.04 7.53E 03
43 cg18482268 POU4F3 5 145 699 158  0.04 4.62E 03
44 cg20969846 DIDO1 20 61 040 666 0.04 4.34E 03
45 cg00347904 SCUBE3 6 35 290 486  0.05 1.78E 02
46 cg26799474 CASP8 2 201 807 196 0.04 5.41E 03
47 cg07584959 THRAP5 19 843937  0.04 1.44E 02
48 cg19235307 MBD4 3 130 642 844  0.04 1.26E 02
49 cg11861730 ETS1 11 127 897 893 0.04 8.97E 03
50 cg21410991 ISL1 5 50 714 208 0.03 1.52E 03
Abbreviations: ASD, autism spectrum disorder; MZ, monozygotic.
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 0.04, Po0.00004). Interestingly, while the overall average
difference at this locus is small, the range of within-twin
methylation difference is much greater (Db ranges from  0.12
to 0.6) and that the direction of effect is strikingly consistent
across the majority of individual twin pairs, with 25 out of 32
discordant pairs (78%) demonstrating trait-related hypomethyla-
tion (Supplementary Figure 7).
Between-group analyses identiﬁed additional ASD-associated
DMRs
Our study design also permitted us to examine group-level DNA
methylation differences between ASD cases and controls. Unlike
the within-pair discordant MZ twin design, between-group DNA
methylation differences can be attributable to both genetic and
environmental factors. Given the known gender difference in DNA
methylation across the X chromosome, these analyses were
restricted to probes on the autosomes (N¼ 22 678) to minimize
gender-induced biases.
Numerous DNA methylation differences were observed
between ASD cases and controls. Supplementary Table 6a and
Supplementary Figure 8 highlight the CpG sites showing the
largest absolute DNA methylation differences (mean DbX0.15)
between ASD cases and unrelated control samples. The top case–
control ASD-associated DMR was located upstream of MGC3207
(cg16474696), which was signiﬁcantly hypomethylated in ASD
cases compared with control samples (mean Db¼  0.24,
Po0.0002). In addition to MGC3207, large signiﬁcant ASD-
associated differences were observed in several other loci,
including CpG sites near OR2L13 (cg20507276; mean Db¼ 0.18)
and C14orf152 (cg20022541; mean Db¼  0.16, data not shown).
Veriﬁcation experiments were conducted on MGC3207 and
OR2L13 using bisulphite-pyrosequencing conﬁrming a high
correlation (r¼ 0.91 and 0.86, for MGC3207 (total N¼ 33) and
OR2L13 (total N¼ 35), respectively) in DNA methylation levels,
detected using the Inﬁnium microarray and pyrosequencing
platforms. Although our list of DMRs was stringently ﬁltered to
exclude probes containing known polymorphic SNPs,29 several of
the top-ranked case–control DMRs, including cg16474696 and
cg20507276, demonstrated patterns of DNA methylation consis-
tent with DNA sequence effects, suggesting that they may be
mediated by cis effects on DNA methylation34 or potentially reﬂect
technical artefacts caused by uncatalogued sequence variation in
probe binding sequences. To exclude the latter for MGC3207, we
sequenced genomic DNA across the DMR in a range of samples
showing differential methylation and identiﬁed no obvious
polymorphic DNA sequence variation in the immediate vicinity
of the probe.
Epigenetic differences identiﬁed between sporadic and familial
ASD cases
ASD is an aetiologically heterogeneous syndrome and can occur
both as a sporadic and a familial disorder. Recent CNV analyses
report considerably higher frequencies of de novo variation in
simplex compared with multiplex ASD families,35 suggesting that
they represent genetically distinct classes. To test whether these
are epigenetically distinct, we compared DNA methylation
between individuals with sporadic ASD (where ASD is reported
in only one member of the MZ twin pair; N¼ 6) and individuals
with familial ASD (as observed in concordant ASD MZ twin pairs;
N¼ 10). The genes most proximal to the 50 top-ranked
Figure 2. DNA methylation differences (Db; autism spectrum disorder (ASD) twin minus well twin) for the top 10 ASD-associated differentially
methylated CpG sites in six ASD-discordant monozygotic (MZ) twin pairs.
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differentially methylated CpG sites from this analysis are listed in
Supplementary Table 6b. The top differentially methylated CpG
site (cg07665060) is located upstream of C19orf33, which was
signiﬁcantly hypomethylated in individuals affected by sporadic
ASD compared with those affected by familial ASD (mean Db¼
 0.12, Po0.0008) (Supplementary Figure 9). Interestingly,
signiﬁcant DNA methylation differences were also observed near
several genes that have been previously implicated in ASD,
including MBD4, AUTS2 and MAP2.
There is some overlap in DMRs across analytical groups
Table 2 provides a full list of top-ranked DMRs demonstrating
overlap between analytical groups and highlighting their potential
relevance to different autism-associated phenotypes. Interestingly,
the top-ranked locus from the ASD-discordant twin analysis,
located near NFYC, was also differentially methylated in the case–
control analysis (mean Db¼ 0.04, Po0.003). Furthermore, we
identiﬁed signiﬁcant DNA methylation differences in the MBD4
promoter in both ASD-discordant twin analysis and sporadic
versus familial ASD analysis, suggesting that MBD4 methylation
may have functional relevance to sporadic ASD. For each of the 50
top-ranked probes in each analysis category, Supplementary
Table 7 lists their corresponding rank across the other analysis
groups; although there is some overlap across groups (and each
ranked list is positively, although modestly, correlated; Supple-
mentary Table 8), few CpG sites are consistently altered across
multiple analytical groups.
Quantitative autistic trait scores are correlated with DNA
methylation at multiple CpG sites
Supplementary Figure 1 shows the distribution of total CAST and
its three trait subscale scores across our samples. Initial analyses
highlighted a strong correlation between DNA methylation and
CAST score at multiple CpG sites (Supplementary Table 9). Further
analysis showed that many of these correlations are inﬂuenced by
extreme DNA methylation levels and phenotypic scores exhibited
by one male ASD-concordant MZ twin pair (Figure 3a and
Supplementary Figure 10). These twins are extreme outliers for
CAST score (both scored 29 out of a maximum score of 31) and
DNA methylation at multiple CpG sites (Supplementary Figure 11),
and both have a history of pervasive developmental problems,
with severe behavioural phenotypes and early-appearing IQ
deﬁcits, with special deﬁcits in language. Given the existing link
between highly penetrant CNVs and severe ASD, we tested
whether the extreme patterns of DNA methylation in these two
twins were associated with the presence of genomic alterations.
Interestingly, high-density SNP microarray analysis revealed sig-
niﬁcant structural genomic alterations at multiple loci, with CNVs
detected in regions previously implicated in ASD (Supplementary
Table 10).
DNA methylation at multiple CpG sites remained signiﬁcantly
correlated with CAST scores even after this extreme twin pair was
excluded from analyses (Supplementary Table 11 and Figure 3b),
suggesting that they do not necessarily represent epigenetic/
phenotypic ‘outliers’ but have DNA methylation levels (and
phenotypic scores) at the extreme end of a true quantitative
spectrum. For example, there is a strong correlation between DNA
methylation at cg07753644 in P2RY11 and total CAST score in both
analyses (with extreme twin pair: r¼ 0.44; P¼ 0.000009; without
extreme twin pair: r¼ 0.35; P¼ 0.0006). Furthermore, DNA
methylation at cg16279786 in the known ASD susceptibility locus,
NRXN1, is signiﬁcantly correlated with social autistic trait score
in both analyses with (r¼  0.41; P¼ 0.00003) and without
(r¼  0.28; P¼ 0.007) the extreme twin pair.
DISCUSSION
This study represents the ﬁrst comprehensive analysis of DNA
methylation differences in MZ twins discordant for ASD and
autism-related traits using a genome-wide approach. We report
ASD-associated DNA methylation differences at numerous CpG
sites, with some DMRs consistent across all discordant twin pairs
for each diagnostic category and others speciﬁc to one or two
twin pairs, or one or two autism-related traits. Although sporadic
cases of ASD appear to be epigenetically distinct to familial cases
of ASD, some DMRs are common across both discordant MZ twin
and case–control analyses. We also observed that DNA methyla-
tion at multiple CpG sites was signiﬁcantly correlated with
quantitatively rated autistic trait scores, with our analyses
identifying one MZ twin pair, concordant for a very severe autistic
phenotype, that appear to represent epigenetic outliers at
multiple CpG sites across the genome. Interestingly, both
individuals harbour numerous CNVs in genomic regions previously
implicated in autism. Given the important role of epigenetic
mechanisms in regulating gene expression, it is plausible that, like
Table 2. Differentially methylated loci highlighted from multiple analytic groups and their relevance to ASD phenotype
Associated phenotype Reported in analyses Gene
ASD (1) Case versus control
(2) ASD-discordant twins
NFYC, PTPRCAP
(1) Sporadic versus familial ASD
(2) ASD-discordant twins
MBD4, RNF185, TINF2
Social autistic traits (1) Discordant twins for social autistic traits
(2) Combined autism group
AFF2, GNB2, GRB2, MAP4, PDHX, PIK3C3, SMEK2, THEX1
Autistic RRBIs (1) Discordant twins for RRBIs
(2) Combined discordant group
(3) ASD-discordant twins
TCP1
(1) Discordant twins for RRBIs
(2) Combined discordant group
ANKS1A, APXL, BPI, EFTUD2, NUDCD3, SNRPN, SOCS2
Communication autistic traits (1) Discordant twins for communication autistic traits
(2) Case versus control
NUP43
(1) Discordant twins for communication autistic traits
(2) Combined discordant group
CCT6A, CEP55, FCJ12505, SRF
Abbreviations: ASD, autism spectrum disorder; RRBI, restricted repetitive behaviours and interests.
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CNVs, methylomic variation could mediate disease susceptibility
via altered gene dosage. Our hypothesis-free experimental design
allowed us to identify disease-associated DNA methylation
differences at loci not previously implicated in ASD, although we
also found evidence for epigenetic changes at several genes
previously implicated in autism.
Our ﬁndings have several implications for our understanding
about the aetiology of ASD. First, they document the presence of
numerous DNA methylation differences in MZ twins discordant for
ASD and ASD-related traits, as well as between autistic individuals
and control samples. This concurs with ﬁndings from a previous
ASD-discordant twin study23 and further supports the association of
Figure 3. (a) The top 10 CpG sites showing the most significant correlation with total Childhood Autism Symptom Test (CAST) score. Each
circle represents a sample. For some loci, the high correlations are influenced by extreme DNA methylation and CAST scores from a single pair
of autism spectrum disorder (ASD)-concordant twins (denoted as blue triangles). (b) Significant correlation between P2RY11 and NRXN1 DNA
methylation and quantitative autistic trait scores remains when the extreme twin pair was excluded. Solid and dashed lines represent results
from correlation analysis including and excluding the extreme twin pair, respectively.
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variable DNA methylation with phenotypic differences between
genetically identical individuals.21,22 Second, the observed DNA
methylation differences in MZ twins discordant for ASD and ASD-
related traits, who are otherwise matched for genotype, shared
environment, age, sex and other potential confounders, highlight
the role of non-shared environmental and stochastic factors in the
aetiology of autism. These ﬁndings concur with mounting data
suggesting that environmentally mediated effects on the epige-
nome may be relatively common and important for disease.36 Third,
our data suggest that although DNA methylation at some CpG sites
is consistently altered across the entire set of discordant twins,
differences at other CpG sites are speciﬁc to certain symptom
groups, with considerable overall epigenetic heterogeneity between
the three domains of autistic traits. These ﬁndings are in line with
recent genetic research demonstrating signiﬁcant genetic
heterogeneity between the three core symptoms of ASD.4,6
Fourth, the analysis of individual ASD-discordant twin pairs
suggests that there is also considerable familial heterogeneity,
with rare epigenetic alterations of large magnitude being potentially
associated with ASD. These ﬁndings are not entirely surprising given
the known heterogeneous nature of ASD revealed by molecular
genetic studies,3 with an important role for highly penetrant rare
genomic alterations, especially de novo mutations. Fifth, the
identiﬁcation of signiﬁcant correlations between DNA methylation
and autism symptom scores across our sample cohort suggests that
there is a quantitative relationship between the severity of the
autistic phenotype and epigenetic variation at certain loci. This
reinforces the view of autism as the quantitative extreme of a
phenotypic spectrum and highlights the potential use of epigenetic
biomarkers as a predictor for severity of symptoms, although the
accuracy, sensitivity and speciﬁcity of such predictors would
require extended investigation. Finally, in addition to implicating
a number of novel genes in the aetiology of ASD, we identiﬁed
ASD-associated differential DNA methylation in the vicinity of
multiple loci previously implicated in the pathogenesis of autism in
genetic studies, including AFF2, AUTS2, GABRB3, NLGN3, NRXN1,
SLC6A4 and UBE3A (see Supplementary Table 12 for a comprehen-
sive list).
This study has several strengths. First, our unique sample
consisted of MZ twin pairs discordant for autism and ASD-related-
traits, in addition to age-matched concordant MZ twin pairs (for
both ASD and low CAST score). It allowed us to perform a
comprehensive analysis of the role of DNA methylation in ASD and
ASD-related traits controlling for genotype, age, sex and other
potential confounders. Second, by undertaking a genome-wide
approach using a robust and reliable array platform, we were able to
uncover phenotype-relevant differentially methylated loci in geno-
mic regions that are both novel and have been previously
associated with ASD. Third, our analysis of 32 discordant MZ
twin pairs is relatively large compared with other discordant
twin studies performed for other complex disease phenotypes;
in this regard, for example, the only other ASD-discordant
twin study assessed only three MZ twin pairs.23 Finally, we
were able to complement our discordant-twin analyses by
assessing group-level differences between ASD cases and controls,
and also examining the relationship between DNA methylation and
quantitatively rated trait scores across our entire sample cohort.
This study also has a number of limitations that should be
considered when interpreting the results. First, although this is the
largest and most comprehensive study of epigenetic variation in
ASD performed to date, the sample size for each subgroup is
small, in part because truly discordant MZ twin pairs are relatively
rare. Although none of the reported differentially methylated loci
reached a Bonferroni-corrected P-value cutoff (P¼ 2.13E–05 for
discordant-twin analysis and P¼ 2.20E–05 for between-group
analysis), this statistical approach is likely to be too conservative,
especially given the non-independence of CpG sites37 and the
small numbers of samples tested in each group. In this study, a
combined analytic approach, taking into account the signiﬁcance
and the extent of methylation change, was used to identify
differentially methylated loci that have potentially real, biological
relevance to ASD. This analytic approach is widely used in
genome-wide gene expression studies and is reported to produce
gene lists of higher reproducibility and biological relevance
compared with the convention method that relies solely on
statistical signiﬁcance.30 This notion is supported by the
identiﬁcation of differentially methylated loci near numerous
genes previously implicated in ASD. Nonetheless, given the
relatively small subgroup sample size, replication in larger
samples is needed. Second, genome-wide DNA methylation
proﬁling was performed on DNA extracted from whole blood,
controlled for cell count, rather than the brain. Unfortunately,
there is no archived collection of post-mortem brain samples from
ASD-discordant MZ twins. Although there are known tissue-
speciﬁc differences in DNA methylation proﬁles, recent studies
suggest that disease-associated epimutations may be detectable
across tissues,38 and our recent work suggests that some
between-individual epigenetic variation is conserved across
brain and blood.39 Furthermore, ASD-associated epimutations
have been demonstrated to be detectable both in the brain and in
peripheral tissues (that is, blood).13,23 Moreover, our identiﬁcation
of DMRs in the vicinity of genes previously implicated in autism
supports the notion that disease-relevant gene network and
pathways can be identiﬁed from peripheral samples. Nonetheless,
it would be informative for future studies to assess whether
disease-associated epimutations reported from this study are also
present in brain samples from ASD patients. Third, informations
pertaining to the amniotic and chorionic status of our twin
samples are unavailable, preventing us from further dissecting the
epigenetic similarity/dissimilarity between twins sharing their
placenta and/or amniotic sac. Fourth, the genome-wide platform
used for this study (the Illumina 27K array), although robust and
highly reliable,28 has a somewhat limited density of probe
coverage, assaying only one or two CpG sites per gene. Future
studies should take advantage of recent advances in genomic
proﬁling technology and perform a more in-depth examination of
methylomic differences associated with ASD. Finally, it is difﬁcult
to draw conclusions about causality for any of the ASD-associated
DMRs identiﬁed in this study, in part, because we do not have
corresponding RNA expression data, or DNA samples from the
twins taken before they became discordant for ASD. It is thus
plausible that many of the identiﬁed changes have occurred
downstream of ASD, for example, resulting from exposure to
medications commonly used to treat autistic symptoms. In fact,
there is mounting evidence that many drugs used to treat
neuropsychiatric disorders induce epigenetic changes.40 Such
medication-induced changes could still be interesting; an
understanding of the pathways via which these drugs work may
provide information about the neurobiological processes involved
in disease. The ideal study design, however, would assess DNA
methylation changes in the brain longitudinally during individuals’
transition into ASD, although such a study does not appear
feasible at present.
In summary, this is the ﬁrst large-scale study to examine the role
of genome-wide DNA methylation in ASD and ASD-related traits.
Our ﬁndings show that: (1) there are numerous DNA methylation
differences between MZ twins discordant for ASD and ASD-related
traits, as well as between autistic individuals and control samples;
(2) many of these DMRs are located in the vicinity of both novel
genes and loci that have been previously implicated in ASD; (3)
the nature of ASD-associated epimutations is complex with high
heterogeneity between individuals; (4) there is high epigenetic
heterogeneity between the triad of impairments that deﬁne ASD;
and (5) there is a quantitative relationship between the severity of
the autistic phenotype and DNA methylation at speciﬁc CpG sites
across the genome. Overall, our ﬁndings from this study provide
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further support for the potential role of DNA methylation in ASD
and ASD-related traits.
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